The latest figures on uptake of rivals to AbbVie's Humira in the US show adalimumab biosimilars beginning to capture significant market share from the originator after an initially slow start in 2023.

Celltrion shrugged off challenges from smaller biosimilars players, calling out “overheated competition from new entrants” as it delivered its results and strategic developments for the second quarter of 2024, including pipeline updates paving the way for trials for its proposed Keytruda and Cosentyx biosimilars.

The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

After acquiring a majority stake in ProteoVant last year, South Korea's SK Biopharm is continuing to hunt for new modalities and is now moving into the hot radiotherapeutics area through a deal with Full-Life Technologies.